September 17, 2025NeoplasmaOpen Access

Synergistic effects of histone deacetylase inhibitor chidamide and BCL-2 inhibitor venetoclax in activating the p53 pathway in diffuse large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This research demonstrates that chidamide enhances venetoclax effects in DLBCL, promoting apoptosis and cell cycle arrest.

Chidamide and venetoclax treatment significantly enhances p53 expression and apoptosis in DLBCL cells, leading to effective cell cycle arrest.
Combination therapy shows IC50 values of 3.54 μM for chidamide and 0.67 μM for venetoclax in SUDHL-4 cells, indicating potency against tumors.
The study utilizes in vitro methods including western blot, flow cytometry, and CCK-8 assays to assess treatment effects and molecular mechanisms.
Results suggest that targeting the p53-p21 pathway could represent a promising therapeutic strategy for treating diffuse large B-cell lymphoma.

Song et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 17, 2025NeoplasmaOpen Access

View Full Paper

Ask AI

Bookmark

Authors

This research demonstrates that chidamide enhances venetoclax effects in DLBCL, promoting apoptosis and cell cycle arrest.

Chidamide and venetoclax treatment significantly enhances p53 expression and apoptosis in DLBCL cells, leading to effective cell cycle arrest.
Combination therapy shows IC50 values of 3.54 μM for chidamide and 0.67 μM for venetoclax in SUDHL-4 cells, indicating potency against tumors.
The study utilizes in vitro methods including western blot, flow cytometry, and CCK-8 assays to assess treatment effects and molecular mechanisms.
Results suggest that targeting the p53-p21 pathway could represent a promising therapeutic strategy for treating diffuse large B-cell lymphoma.

Song et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark